# US 2021/0363527 A1 · PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING MIR-324 and TUT4/7 EXPRESSION MODULATORS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0363527 A1
- Document ID: US20210363527A1
- Status: Published application
- Kind: A1
- Application number: 17/385,277
- Filed: 2021-07-26
- Published: 2021-11-25
- Earliest claimed: 2019-02-26
- Assignees: Seoul National University R&Db Foundation; Institute for Basic Science
- Applicants: Seoul National University R&Db Foundation; Institute for Basic Science
- Inventors: V. Narry KIM; Haedong KIM; Jimi KIM
- Web page: https://patentgrep.com/patent/US20210363527A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61P 35/00: Antineoplastic agents
- C12N 9/1282: {RNA uridylyltransferase (2.7.7.52)}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Y 207/07052: RNA uridylyltransferase (2.7.7.52)
- G01N 33/6854: {Immunoglobulins}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2320/30: Special therapeutic applications
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising miR-324 and TUT4/7 expression modulators, wherein the pharmaceutical composition of the present invention can prevent cell division and hinder cancer development by inhibiting the function of TUT4/7, and can increase the amount of miR-324-5p and suppress the function of miR-324-3p.1, and therefore can be effectively used for prevention, treatment, or diagnosis of cancer.

## Claims

### Claim 1

Method of treating cancer, comprising administering to a subject in need thereof a pharmaceutical composition for preventing or treating cancer, the composition comprising a microRNA(miRNA) which is comprising i) a miR-324-5p or an isoform thereof, and ii) a miR-324-3p or an isoform thereof:
wherein the i) miR-324-5p comprising the nucleotide sequences of SEQ ID NO: 47 at the 5′ end, and a total of 20 to 24 nucleotide sequences;
wherein the ii) miR-324-3p is,
a) the first base from the 5′ end may be C or G;
b) the first base from the 5′ end is complementary to the 20th base from the 5′ end of the miR-324-5p; and
c) the 20th base from the 5′ end may be A, U, or C.

### Claim 2 (depends on 1)

The method of claim 1, wherein the microRNA is in the form of a duplex in which i) miR-324-5p or isoform thereof, and the ii) miR-324-3p or isoform thereof are bounded to each other.

### Claim 3 (depends on 1)

The method of claim 1, wherein the 5′ end of the i) miR-324-5p or isoform thereof, and the ii) miR-324-3p or isoform thereof bonded to phosphate, respectively.

### Claim 4 (depends on 1)

The method of claim 1, wherein the i) miR-324-5p or isoform thereof, comprising the nucleotide sequences of SEQ ID NO: 1 or 32.

### Claim 5 (depends on 1)

The method of claim 1, wherein the ii) miR-324-3p or isoform thereof, comprising the nucleotide sequences of SEQ ID NO: 2, 3, or 33.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cancer is selected from the group consisting of colon cancer, large intestine cancer, lung cancer, liver cancer, stomach cancer, gallbladder cancer, kidney cancer, uterine cervical cancer, endometrial cancer, ovarian cancer, breast cancer, brain cancer, head and neck cancer, and malignant melanoma.

### Claim 7

A method of treating cancer, comprising:
administering to a subject in need thereof a pharmaceutical composition for preventing or treating cancer, the composition comprising at least one selected from the group consisting of:
a nucleic acid composed of the nucleotide sequence of SEQ ID NO: 4; and
a small interfering RNA (siRNA) comprising at least one nucleotide sequence selected from the group consisting of SEQ ID NOS: 5 to 20.

### Claim 8 (depends on 7)

The method of claim 7, wherein the small interfering RNA is in a duplex form in which:
i) a small interfering RNA comprising any one of the nucleotide sequences of SEQ ID NOS: 5 to 8 and a small interfering RNA comprising any one of the nucleotide sequences of SEQ ID NOS: 9 to 12 bind to each other; or
ii) a small interfering RNA comprising any one of the nucleotide sequences of SEQ ID NOS: 13 to 16 and a small interfering RNA comprising any one of the nucleotide sequences of SEQ ID NOS: 17 to 20 bind to each other.

### Claim 9 (depends on 7)

The method of claim 7, wherein the cancer is selected from the group consisting of encephaloma, colon cancer, large intestine cancer, lung cancer, liver cancer, stomach cancer, esophageal cancer, pancreatic cancer, gallbladder cancer, kidney cancer, bladder cancer, prostate cancer, testis cancer, uterine cervical cancer, endometrial cancer, choriocarcinoma, ovarian cancer, breast cancer, thyroid cancer, brain cancer, head and neck cancer, and malignant melanoma.

### Claim 10

A method of diagnosing cancer, comprising measuring a level of:
i) at least one miRNA selected from the group consisting of miR-324-5p and miR-324-3p.1; or
ii) at least one gene mRNA or protein thereof selected from the group consisting of TUT4 (terminal uridylyl transferases 4) and TUT7 (terminal uridylyl transferases 7).

### Claim 11 (depends on 10)

The method of claim 10,
wherein the measuring step is performed by an agent that measures the level of miRNA;
wherein the agent comprises a primer or a probe which bind specifically to the at least one miRNA.

### Claim 12 (depends on 10)

The method of claim 10,
wherein the measuring step is performed by an agent that measures the level of gene mRNA;
wherein the agent for measuring an mRNA level comprises a primer or a probe which bind specifically to at least one mRNA of TUT4 and TUT7.

### Claim 13 (depends on 10)

The method of claim 10,
wherein the measuring step is performed by an agent that measures the level of protein;
wherein the agent for measuring a protein level comprises an antibody binding specifically to at least one protein of TUT4 and TUT7.
